c.moreau98/100
Consistency: 8 lots, purity band under 0.9 points wide. Janoshik report held on file, figures match published.
GSP — GenScript Biotech Corporation
Nanjing, CN · established 2002. The index holds 180 assay reports across 32 batches and 22 compounds, contributed by 6 laboratories. Every figure below is computed from those records and from nothing else.
Where GSP sells
GenScript Biotech Corporation sells from its own storefront. The link is marked nofollow and sponsored: it exists so the figures on this scorecard can be read against what the supplier itself publishes. The index is paid nothing for it and a link is not an assessment.
Visit GSP at genscriptpeptides.com →
Every figure above describes lots the index has seen. It says nothing about the lot you are offered, and the only check that does is the one on the certificate against the vial.
Block 1
Identification
Business facts, held constant across the index and not derived from the data. The index sells nothing and takes no supplier payment for placement; the storefront link below is marked nofollow and sponsored so a record can be checked against the seller, and is not a recommendation.
- Legal name
- GenScript Biotech Corporation
- Short code in this index
- GSP
- Also known as
- GSP · GenScript Peptides · GenScript Biotech · 金斯瑞生物科技
- Domain
- genscriptpeptides.com →
- City
- Nanjing
- Region
- Jiangsu
- Country
- CN
- Established
- 2002
- First record in index
- 10 Feb 2024
- Most recent record
- 15 Oct 2026
Block 1b
Dispatch and regional stock
Counted from the chain-of-custody line on this supplier's own records, which names the route each vial travelled to the laboratory, and from the on-record reviews below. The index has no sight of any supplier's warehouse network and publishes none.
Domestic-warehouse route
20.0%
n=180
Retail, shipped to the buyer
70.6%
n=180
Direct to the laboratory
3.9%
n=180
Median courier leg, direct despatch
9d
n=7
| Route to the laboratory | Records | Share |
|---|---|---|
| Domestic warehouse despatch | 36 | 20.0% |
| Retail purchase, shipped to the buyer | 94 | 52.2% |
| Retail purchase via a third-party forwarder | 33 | 18.3% |
| Supplier despatch direct to the laboratory | 7 | 3.9% |
| Laboratory retained-sample archive | 10 | 5.6% |
Every record here carries a chain-of-custody line and that line names the route the vial travelled. Of the 180 GSP records the index holds, 36 reached the contributing laboratory from a domestic warehouse rather than as a cross-border consignment, covering 12 of the 22 compounds GSP is represented by here — Semaglutide, AOD-9604, Retatrutide, ARA-290, Tesamorelin, Vilon and 6 further compounds. Those are the GSP lines this index has actually seen arrive from regional stock, and they are a count of consignments rather than a stock listing: a line missing from them may simply never have been submitted for assay.
One contributor on the record below documents GSP stock held in Netherlands, with a transit of 6 working days against a quoted 7. Netherlands is the only regional stock location named anywhere in GSP's record here, and one consignment described by one buyer is exactly that. It is not a warehouse list and the index has not verified it.
The index measures nothing about lead time — it assays material, it does not buy it. What it has is GSP's own reviewers: 2 of the 14 on-record reviews state a quoted window and what happened against it. Where GSP despatched a sample direct to a laboratory, the courier leg ran a median 9 days across 7 such consignments — that is a transit time the index can see, and it is not the same thing as a lead time. The reviews are reproduced in full in Block 11.
Block 2
Headline statistics
Each figure carries the n it was computed from. The n= badge next to a statistic is the number of records it was computed from. Below n=8 the badge is amber. Below n=3 the statistic is suppressed and the individual values are shown instead.
Median purity
99.02%
n=180
Interquartile range
1.00pp
n=180
10th percentile
98.07%
n=180
Pass rate vs index spec
98.3%
n=180
Median recovery vs claim
96.9%
n=105
Median water
5.64%
n=180
Median |mass error|
2.7ppm
n=152
Records carrying a flag
17.2%
n=180
Block 3
Reproducibility across independent tests of one lot
Where the same physical lot was assayed more than once, the spread between those results is a property of the material and the fill, not of the market. It is the rarest and most informative statistic on this page, and it exists only for lots someone tested twice.
Median within-batch spread
0.75pp
n=20
Index median spread
0.67pp
n=28
Lots tested 3+ times
20
n=32
Across the 20 GSP lots in the index with three or more independent assays, the median spread between the highest and lowest purity result on one lot is 0.75 pp. Interpreting that number requires the laboratory repeatability figures: the best contributing laboratory here repeats to 0.16 pp and the worst to 0.34 pp, so a within-lot spread under about 0.5 pp is indistinguishable from measurement noise and a spread above 1 pp is a statement about the material.
Block 4
Supplier certificate against independent measurement
The supplier's own COA purity figure for a lot, minus the median of the index's independent observations of the same physical lot. Positive means the certificate reads higher than the measurement. Rule AX-R05 fires above 1.5 pp.
Median COA divergence
+0.08pp
n=32
Index median divergence
+0.06pp
n=28
Divergences in the supplier's favour
66%
n=32
Divergences beyond 1 pp
0%
n=32
Block 5
Provenance — where the tested material came from
Supplier-supplied samples are weaker evidence than independently purchased ones, because the supplier chose the vial. The index measures the size of that effect rather than assuming it.
Buyer-sourced median
98.97%
n=163
Supplier-supplied median
99.71%
n=7
Supplier-supplied share of records
3.9%
n=180
Block 6
Documentation completeness
The score is not an opinion about paperwork. Each component is the share of GSP batches in the index whose certificate carries that field, weighted as set out on the scoring rubric.
Documentation score
91/100
n=32
Index median score
85/100
n=28
| Certificate field | Batches carrying it | Rubric weight | |
|---|---|---|---|
| Purity figure stated | 100% | 25 points | |
| Analytical method stated (column, gradient, wavelength) | 81% | 25 points | |
| Peptide content stated | 66% | 20 points | |
| Endotoxin stated | 41% | 15 points | |
| Named impurities rather than a total | 69% | 15 points |
Block 7
Coverage by compound
The delta column is this supplier's median minus the index-wide median for the same compound, which is the only comparison worth making: comparing a supplier's aggregate against another supplier's aggregate compares their product mixes as much as their process control.
| Compound | Class | Reports | Median % | Index median % | Δ (pp) | Index spec | Pass % |
|---|---|---|---|---|---|---|---|
| Semaglutide | Incretin | 23 | 98.87 | 98.89 | -0.02 | 97.0 | 100 |
| AOD-9604 | Metabolic | 20 | 98.66 | 99.29 | -0.63 | 98.0 | 100 |
| Retatrutide | Incretin | 16 | 97.83 | 98.37 | -0.54 | 96.5 | 100 |
| Semax | Neuroactive | 15 | 99.93 | 99.46 | +0.47 | 98.5 | 100 |
| SLU-PP-332 | Non-peptide | 12 | 99.00 | 98.88 | +0.13 | 98.0 | 100 |
| Tesamorelin | Growth-hormone | 12 | 98.28 | 98.29 | -0.01 | 97.0 | 100 |
| GHRP-6 | Growth-hormone | 11 | 99.57 | 99.54 | +0.03 | 99.0 | 100 |
| MK-677 (Ibutamoren mesylate) | Non-peptide | 10 | 99.47 | 99.49 | -0.02 | 98.5 | 100 |
| PT-141 (Bremelanotide) | Melanocortin-receptor | 9 | 99.64 | 99.38 | +0.26 | 98.5 | 100 |
| Survodutide | Incretin | 8 | 98.31 | 98.38 | -0.07 | 96.5 | 100 |
| BPC-157 | Tissue-repair | 8 | 99.09 | 99.16 | -0.07 | 98.0 | 100 |
| TB-500 | Tissue-repair | 7 n=7 | 99.09 | 99.53 | -0.44 | 98.5 | 86 |
| Selank | Neuroactive | 6 n=6 | 99.54 | 99.59 | -0.05 | 99.0 | 100 |
| ARA-290 | Tissue-repair | 5 n=5 | 99.45 | 99.42 | +0.03 | 98.0 | 100 |
| NAD+ | Non-peptide | 5 n=5 | 99.74 | 99.28 | +0.46 | 97.0 | 100 |
| Vilon | Short | 4 n=4 | 99.28 | 99.65 | -0.37 | 99.0 | 75 |
| Hexarelin | Growth-hormone | 3 n=3 | 99.01 | 99.59 | -0.58 | 99.0 | 67 |
| Thymosin α1 | Tissue-repair | 2 n=2 | n<3 | 99.40 | — | 97.5 | 100 |
| Afamelanotide | Melanocortin-receptor | 1 n=1 | n<3 | 99.06 | — | 98.0 | 100 |
| Liraglutide | Incretin | 1 n=1 | n<3 | 99.00 | — | 97.5 | 100 |
| Oxytocin | Hypothalamic | 1 n=1 | n<3 | 99.81 | — | 98.5 | 100 |
| LL-37 | Tissue-repair | 1 n=1 | n<3 | 98.90 | — | 96.5 | 100 |
Full per-compound breakdown with distributions and caveats →
Block 8
Quarterly trend
Submission volume is not market share and a quarterly median is not a trend unless the compound mix held still. Both caveats apply to every row below.
Median purity by quarter
Quarters with fewer than two purity records are gaps in the line rather than zeroes.
Coverage growth
Records added per quarter. Growth here is index coverage, not supplier volume.
| Quarter | Batches | Reports | Median purity | Range | Flagged |
|---|---|---|---|---|---|
| 2024-Q1 | 2 | 6 | 99.02 | 98.79–99.41 | 1 |
| 2024-Q2 | 2 | 19 | 98.96 | 98.44–99.71 | 4 |
| 2024-Q3 | 1 | 13 | 99.93 | 99.50–99.93 | 1 |
| 2024-Q4 | 2 | 3 | 99.77 | 98.30–99.93 | 0 |
| 2025-Q1 | 3 | 26 | 98.98 | 98.06–99.93 | 3 |
| 2025-Q2 | 3 | 26 | 98.08 | 97.39–99.35 | 2 |
| 2025-Q3 | 4 | 17 | 99.57 | 98.84–99.93 | 2 |
| 2025-Q4 | 5 | 27 | 98.85 | 98.30–99.55 | 13 |
| 2026-Q1 | 3 | 9 | 99.42 | 98.59–99.77 | 1 |
| 2026-Q2 | 6 | 26 | 99.31 | 97.97–99.92 | 3 |
| 2026-Q3 | 1 | 8 | 98.31 | 97.92–99.91 | 1 |
Block 9
Which laboratory produced these numbers
Laboratories disagree with each other by a measured amount. A supplier tested mostly by one laboratory carries that laboratory's offset in its aggregate, and the adjusted column removes it.
| Laboratory | Reports | Median purity | Lab bias (pp) | Bias-adjusted |
|---|---|---|---|---|
| Janoshik | 63 | 99.01 | +0.00 | 99.01 |
| PeptideMeter | 34 | 99.00 | -0.05 | 99.05 |
| Medutest | 29 | 99.20 | +0.08 | 99.12 |
| VendorInvestigate | 26 | 98.91 | -0.11 | 99.02 |
| Nordanalyt | 16 | 99.04 | +0.02 | 99.02 |
| Kestrel | 12 | 99.28 | +0.24 | 99.04 |
Bias figures are estimated from paired same-lot comparisons and are published with their confidence intervals on inter-lab agreement.
Block 10
What this data does and does not show
Block 11
On-the-record reviews 14
Reviews are signed statements from index contributors about their own testing of this supplier's material. They are opinions attached to evidence, and they are not used in any statistic on this page.
94.0/ 100703 ratings across the index network
ha.mwangi96/100
Certificate carries counter-ion identity and content, reported as trifluoroacetate with a figure. Complete against the index minimum data set at first issue. Research use. Not for human administration.
n.beaulieu98/100
Lot GSP-26-118 submitted to Janoshik. Declared 98.5%, reported 98.7%. Delta inside method repeatability. Janoshik report held on file.
ay.boateng95/100
Transit 6 days from stock held in Netherlands against a quoted 7. Customs documentation correct at first presentation.
ro.okwuosa97/100
Release signed and dated, named individual. Per-milligram figure calculated against the certificate rather than against nominal fill.
d.oyelaran82/100
Analytical record complete and unremarkable. Process observation logged separately: written quotation for a custom sequence issued at 5 working days against same-day acknowledgement on catalogue enquiries. Manufacture completed inside the quoted schedule. Rating reflects the process observation only.
fr.chukwu96/100
Related-substances table itemised by impurity with assigned retention times. Not aggregated. Submitted to the index in full.
ju.coelho97/100
Blind submission of semaglutide 5 mg to Medutest, origin withheld. 98.4% against 98.2% declared. Figures as reported by the named service.
y.erdogan96/100
Fill uniformity: 12 units weighed against declared fill, all within 2%. No further comment.
j.hartmann98/100
Cross-check: PeptideMeter and VendorInvestigate, same lot, agreement to 0.1 points. Both agree with the declared figure. Record covers one lot.
am.ekstrom93/100
Synthesis record supplied in full on request, attached rather than summarised, purification step named. Independent verification of individual lots still required.
c.kjaer90/100
Reconstitution: 8 of 9 units clear on contact, 1 transient haze resolving on standing. Single consignment. Logged as an observation, not a finding.
t.nakamura97/100
Cold chain intact. Phase-change pack solid at arrival, day 5. Evidence base adequate for a rating on this criterion.
k.bakken98/100
Retention: certificate reissued for a lot released 13 months earlier, from supplier records, no justification required. Record covers documentation practice, not material.
Block 12
Most recent records
Block 13
Contributor annotations on GSP records 289
Annotations are this index's only discussion surface: signed technical comments attached to a specific record by a named contributor. They are not moderated for agreement with the index's own arithmetic. The most recent on GSP material are below, each linked to the record it sits on.
Lot GSP-2603-E3156 on the vial matches the certificate that came with it. That is the check every buyer can do in ten seconds and most do not.
A single result at 99.91 % is one draw. What makes a supplier's process legible is the spread across its lots, and that is on the scorecard rather than here. This record is one good point in a distribution worth reading whole.
Strong provenance does not fix small n. One well-sourced record is still one record, and the batch page says how many others exist for GSP-2603-E3156.
A retail vial is also a test of the label. Declared claim 10 mg against what the gravimetry recovers is a question only a purchased vial can answer honestly.
Column temperature shifts selectivity by a few percent per ten degrees on peptides. Where two peaks are this close that is enough to matter and it is rarely on the report.
Doubling column length gains 40 % resolution and doubles the run. On a routine release method that trade is usually declined, and the certificate should say which method was run.
Purity 98.34 % with truncated (2-39) at 1.04 % nearby. Read the pair together: the purity figure and its nearest neighbour are two views of one integration decision.
Mass at -1.7 ppm establishes identity but not content. Absolute content needs a standard or an orthogonal quantitative method, and neither is a mass spectrometer.
Every annotation the index holds on GSP material sits on its own record; the full set is reachable from the record listing and from each contributor's page. To read them against what GSP itself publishes, open genscriptpeptides.com → alongside.
Block 14
Where to buy GSP
GenScript Biotech Corporation sells direct from genscriptpeptides.com. Everything on this page describes lots the index has already seen; the certificate that matters is the one that arrives with the vial you order, and the lot code on it should match the vial. Ask for the lot-specific document rather than the batch-level summary, and ask for the integration report if you intend to reconcile the figure yourself.
Go to the GSP store at genscriptpeptides.com →
Marked nofollow and sponsored. The index is paid nothing for it, takes no commission, and a link is not an assessment. Research compounds. Not medical advice. Nothing on this site is a safety assessment and nothing on it is approved for human use.